Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Exclusion Criteria

• •1. Subject has secondary immunodeficiency or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency; has known hypoalbuminemia (\<3 gm/dL), protein-losing enteropathy, or nephrotic syndrome.
• •2. Subject has ever had a history of severe anaphylactic or anaphylactoid reaction to immunoglobulins or other blood products.
• •3. Subject has a known history of immunoglobulin A (IgA) deficiency and known anti-IgA antibodies, thrombotic event, such as deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism, at any time.
• •4. Subject has received blood products except IGIV, IGSC, or albumin within the previous 12 months or has participated in another study (except for IGIV, IGSC studies) within the previous 4 weeks.
• •5. Subject has had cancer in the past 5 years, except for basal cell or squamous cell cancers of the skin.
• •6. Subject has had a documented active infection within 7 days prior to Screening, or subject is on continuous prophylactic antibiotics.
• •7. Subject is positive for human immunodeficiency virus (HIV)-1 or HIV-2, a positive hepatitis C virus (HCV) or hepatitis B virus (HBV).
• •8. Subject has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 times the upper limit of normal (ULN).
• •9. Subject has serum creatinine \>1.5 times the ULN or a severe chronic condition such as renal failure with proteinuria.
• •10. Subject has anemia with a hemoglobin level ≤8 g/dL.
• •11. Subject has severe neutropenia with neutrophil count ≤1000 per mmᴧ3 or has lymphopenia with \<500 per/ mmᴧ3.
• •12. Subject is taking prednisone at a dose ≥0.15 mg/kg/day and receiving other immunosuppressive drugs or chemotherapy.
• •13. Subject has known atrial fibrillation requiring anticoagulant therapy; congestive heart failure (New York Heart Association Class III/IV); cardiomyopathy; or cardiac arrhythmia associated with thromboembolic events, unstable or advanced ischemic heart disease, or hyperviscosity.
• •14. Subject has known decreased Protein C and/or Protein S levels.
• •15. Subject is positive for antibodies to β2GPI and/or β2GPI DI at Screening.
• •16. Female subject who is pregnant, breast-feeding, or planning a pregnancy during the course of the study.
• •17. A history of epilepsy or multiple episodes of migraine (defined as at least one episode within 6 months of enrolment) not completely controlled by medication, or any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study in the Investigator's opinion.